| 4.6 -0.21 (-4.37%) | 10-04 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.41 | 1-year : | 7.48 |
| Resists | First : | 5.48 | Second : | 6.41 |
| Pivot price | 4.86  |
|||
| Supports | First : | 4.38 | Second : | 3.7 |
| MAs | MA(5) : | 4.92 |
MA(20) : | 4.67 |
| MA(100) : | 5.59 |
MA(250) : | 6.05 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 54.3 |
D(3) : | 64.4 |
| RSI | RSI(14): 48 |
|||
| 52-week | High : | 11.44 | Low : | 2.96 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ELTX ] has closed above bottom band by 29.5%. Bollinger Bands are 41.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.93 - 4.98 | 4.98 - 5.01 |
| Low: | 4.5 - 4.56 | 4.56 - 4.6 |
| Close: | 4.53 - 4.63 | 4.63 - 4.69 |
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.
Tue, 17 Sep 2024
Elicio Therapeutics Reports Inducement Grants - GlobeNewswire
Fri, 13 Sep 2024
Elicio Therapeutics Announces Three Upcoming Presentations - GlobeNewswire
Wed, 28 Aug 2024
Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Yahoo Finance
Mon, 12 Aug 2024
Elicio Therapeutics Announces Closing of Private Placement of $20.0 Million Convertible Note - GlobeNewswire
Fri, 28 Jun 2024
Why Is Elicio Therapeutics (ELTX) Stock Down 36% Today? - InvestorPlace
Fri, 28 Jun 2024
Why Is Cancer Vaccine Developer Elicio Therapeutics Stock Trading Lower On Friday? - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 11 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 28.1 (%) |
| Held by Institutions | 6 (%) |
| Shares Short | 30 (K) |
| Shares Short P.Month | 43 (K) |
| EPS | 0.92 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.16 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -96.9 % |
| Return on Equity (ttm) | -353.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.81 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -36 (M) |
| Levered Free Cash Flow | -22 (M) |
| PE Ratio | 5 |
| PEG Ratio | 0 |
| Price to Book value | -28.75 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.38 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|